for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Aquestive Therapeutics Inc

AQST.OQ

Latest Trade

5.44USD

Change

0.00(0.00%)

Volume

98,447

Today's Range

5.38

 - 

5.87

52 Week Range

2.96

 - 

17.10

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Aquestive Therapeutics Reports Q3 Results And Raises 2019 Guidance

Nov 5 (Reuters) - Aquestive Therapeutics Inc <AQST.O>::AQUESTIVE THERAPEUTICS REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS AND RAISES 2019 GUIDANCE.Q3 REVENUE $12.4 MILLION VERSUS REFINITIV IBES ESTIMATE OF $10 MILLION.SEES FY 2019 REVENUE $45 MILLION TO $47 MILLION.Q3 LOSS PER SHARE $0.74.Q3 EARNINGS PER SHARE ESTIMATE $-0.69 -- REFINITIV IBES DATA.SEES 2019 NON-GAAP ADJUSTED EBITDA LOSS OF $49 MILLION TO $50 MILLION.CASH & CASH EQUIVALENTS AS OF SEPTEMBER 30, 2019 WERE $20.9 MILLION.

Aquestive Therapeutics Reaffirms Full Year 2019 Revenue Guidance

Oct 15 (Reuters) - Aquestive Therapeutics Inc <AQST.O>::AQUESTIVE THERAPEUTICS REAFFIRMS FULL YEAR 2019 REVENUE GUIDANCE AND WILL ANNOUNCE THIRD QUARTER 2019 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS ON NOVEMBER 6, 2019.FY2019 REVENUE VIEW $42.8 MILLION -- REFINITIV IBES DATA.AQUESTIVE THERAPEUTICS - FY 2019 TOTAL REVENUE IS NOW EXPECTED TO BE AT TOP END OF CO'S GUIDANCE RANGE OF $38 MILLION TO $45 MILLION.

Aquestive Therapeutics Q2 Revenue $11.1 Mln Vs $13.9 Mln

Aug 6 (Reuters) - Aquestive Therapeutics Inc <AQST.O>::Q2 REVENUE $11.1 MILLION VERSUS $13.9 MILLION.Q2 LOSS PER SHARE $0.82.REVISING ITS FULL YEAR GUIDANCE AND FINANCIAL OUTLOOK FOR 2019.SEES 2019 TOTAL REVENUES OF $38 MILLION TO $45 MILLION.SEES 2019 NON-GAAP GROSS MARGINS OF 67% TO 69% ON TOTAL REVENUES.SEES 2019 NON-GAAP ADJUSTED EBITDA LOSS OF $50 MILLION TO $52 MILLION.AQUESTIVE THERAPEUTICS SEES 2019 CASH BURN OF ABOUT $60 TO $65 MILLION AFTER CONSIDERING ADJUSTED EBITDA, NET INTEREST EXPENSE AND PRINCIPAL PAID ON DEBT.RAISES FULL YEAR GUIDANCE FOR SUBOXONE-RELATED MANUFACTURING REVENUE.SEES 2019 SUBOXONE AND SANDOZ AUTHORIZED GENERIC MANUFACTURING REVENUE OF $29 MILLION TO $32 MILLION.Q2 EARNINGS PER SHARE VIEW $-0.62, REVENUE VIEW $9.2 MILLION -- REFINITIV IBES DATA.FY2019 REVENUE VIEW $40.4 MILLION -- REFINITIV IBES DATA.

Intelgenx, Aquestive Therapeutics Enter Collaboration Agreement For Tadalafil

May 8 (Reuters) - Aquestive Therapeutics Inc <AQST.O>::INTELGENX AND AQUESTIVE THERAPEUTICS ENTER WORLDWIDE COLLABORATION AGREEMENT FOR TADALAFIL.INTELGENX TECHNOLOGIES CORP - INTELGENX AND AQUESTIVE WILL EACH GRANT TO OTHER EXCLUSIVE WORLDWIDE LICENSES TO THEIR RESPECTIVE INTELLECTUAL PROPERTY.INTELGENX TECHNOLOGIES CORP - DEAL FOR EXCLUSIVE WORLDWIDE LICENSES PROPERTY RELATING TO TADALAFIL ORAL FILM FORMULATION AND MANUFACTURING.INTELGENX TECHNOLOGIES CORP - INTELGENX WILL PAY AQUESTIVE A ROYALTY EQUAL TO 10% OF ALL PAYMENTS RECEIVED BY INTELGENX.

Aquestive Therapeutics Q1 Loss Per Share $0.59

May 8 (Reuters) - Aquestive Therapeutics Inc <AQST.O>::AQUESTIVE THERAPEUTICS REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS.Q1 REVENUE $12.6 MILLION VERSUS REFINITIV IBES ESTIMATE OF $11.6 MILLION.Q1 LOSS PER SHARE $0.59.Q1 EARNINGS PER SHARE ESTIMATE $-0.51 -- REFINITIV IBES DATA.AQUESTIVE IS REAFFIRMING ITS FULL YEAR GUIDANCE AND FINANCIAL OUTLOOK FOR 2019.

Aquestive Therapeutics Announces U.S. FDA Acceptance Of New Drug Application For ALS Oral Treatment

April 16 (Reuters) - Aquestive Therapeutics Inc <AQST.O>::AQUESTIVE THERAPEUTICS ANNOUNCES U.S. FOOD AND DRUG ADMINISTRATION (FDA) ACCEPTANCE OF NEW DRUG APPLICATION FOR RILUZOLE ORAL FILM FOR TREATMENT OF ALS.AQUESTIVE THERAPEUTICS INC - PDUFA (PRESCRIPTION DRUG USER FEE ACT) GOAL DATE IS NOVEMBER 30, 2019.AQUESTIVE THERAPEUTICS INC - COMPANY IS EXPLORING COMMERCIAL OPPORTUNITIES FOR ROF IN U.S. AND ABROAD..

Aquestive Therapeutics Q4 Loss Per Share $0.56

March 14 (Reuters) - Aquestive Therapeutics Inc <AQST.O>::AQUESTIVE THERAPEUTICS, INC. REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS.Q4 REVENUE $16.8 MILLION VERSUS REFINITIV IBES ESTIMATE OF $16.7 MILLION.Q4 LOSS PER SHARE $0.56.Q4 EARNINGS PER SHARE ESTIMATE $-0.51 -- REFINITIV IBES DATA.SEES FULL YEAR 2019 TOTAL REVENUES OF $33 MILLION TO $45 MILLION.SEES FULL YEAR 2019 NON-GAAP ADJUSTED EBITDA LOSS OF $40 MILLION TO $45 MILLION.SEES FULL YEAR 2019 CASH BURN OF APPROXIMATELY $45 MILLION TO $50 MILLION.

Aquestive Therapeutics Provides Update Regarding Suboxone Sublingual Film Litigation

Feb 5 (Reuters) - Aquestive Therapeutics Inc <AQST.O>::AQUESTIVE THERAPEUTICS PROVIDES UPDATE REGARDING SUBOXONE SUBLINGUAL FILM LITIGATION.AQUESTIVE - U.S. COURT DENIED MOTION FOR REHEARING TO REINSTATE PRELIMINARY INJUNCTION AGAINST DR. REDDY'S LABORATORY REGARDING SUBOXONE.AQUESTIVE - DECISION "NOT A JUDGEMENT" IN ONGOING INFRINGEMENT CASES AGAINST DRL AND OTHERS REGARDING POTENTIAL GENERIC PRODUCTS ENTERING U.S. MARKET.

Aquestive Therapeutics Granted Temporary Restraining Order Against Alvogen

Jan 25 (Reuters) - Aquestive Therapeutics Inc <AQST.O>::AQUESTIVE THERAPEUTICS GRANTED TEMPORARY RESTRAINING ORDER (TRO) AGAINST ALVOGEN.AQUESTIVE THERAPEUTICS - TRO TO REMAIN IN PLACE PENDING HEARING ON PRELIM. INJUNCTION MOTION PREVIOUSLY FILED BY CO, INDIVIOR.AQUESTIVE THERAPEUTICS - TRO ENJOINS ALVOGEN FROM INITIATING ANY LAUNCH ACTIVITIES RELATED TO ITS GENERIC BUPRENORPHINE/NALOXONE SUBLINGUAL FILM.AQUESTIVE THERAPEUTICS INC - HEARING ON PI MOTION IS SCHEDULED WITH DISTRICT COURT ON FEBRUARY 7, 2019.

Aquestive Therapeutics Sees FY 2018 Revenue $67 Million

Aquestive Therapeutics Inc <AQST.O>::AQUESTIVE THERAPEUTICS PROVIDES END OF YEAR BUSINESS UPDATE, INCLUDING PROGRESS OF ITS PROPRIETARY CNS ASSETS, FINANCIAL AND LEGAL MATTERS.SEES FY 2018 REVENUE $67 MILLION.SEES END-OF-YEAR CASH AND CASH EQUIVALENTS IN RANGE OF $58 MILLION TO $60 MILLION.EXPECTED NDA FILING FOR EXSERVAN™ (RILUZOLE) ORAL FILM IN JANUARY 2019.PLAN FOR ROLLING SUBMISSION FOR LIBERVANT™ (DIAZEPAM) BUCCAL FILM TO BE SUBMITTED IN JANUARY 2019.AQUESTIVE THERAPEUTICS-SEES BRANDED SUBOXONE(BUPRENORPHINE / NALOXONE) FILM IN U.S. & INTERNATIONAL TO BE MAJOR REVENUE CONTRIBUTOR THROUGH AT LEAST 2023.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up